Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Cancer

Volumn 121, Issue 7, 2015, Pages 1048-1055

  Baron, Frédéric ^a   Labopin, Myriam ^b,c,d   Peniket, Andy ^e   Jindra, Pavel ^f   Afanasyev, Boris ^g   Sanz, Miguel A ^h   Deconinck, Eric ⁱ   Nagler, Arnon ^b,j   Mohty, Mohamad ^b,c,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f CHARLES UNIVERSITY   (Czech Republic)

^g PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^h La Fe University   (Spain)

ⁱ UNIVERSITY HOSPITAL OF BESANÇON   (France)

^j TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

acute myeloid leukemia (AML); busulfan; fludarabine; graft versus host disease (GVHD); melphalan; reduced intensity conditioning (RIC); transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CANCER STAGING; COMPARATIVE STUDY; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; VIDARABINE; YOUNG ADULT;

EID: 84925377506     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29163     Document Type: Article

References (27)

1. Estey EH,. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia. 2013; 27: 1803-1812.
2. Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013; 122: 1384-1394.
3. Baron F, Storb R,. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol. 2007; 14: 145-151.
4. Mohty M, de Lavallade H, El-Cheikh J, et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia. 2009; 23: 194-196.
5. Sorror ML, Appelbaum FR,. Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Expert Rev Hematol. 2013; 6: 547-562.
6. Gale RP, Wiernik PH, Lazarus HM,. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia. 2014; 28: 1949-1952.
7. Oran B, Weisdorf DJ,. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012; 97: 1916-1924.
8. Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Leukemia. 2012; 26: 2462-2468.
9. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997; 89: 4531-4536.
10. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91: 756-763.
11. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008; 26: 577-584.
12. Sandmaier BM, Mackinnon S, Childs RW,. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant. 2007; 13: 87-97.
13. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28: 1878-1887.
14. Chevallier P, Szydlo RM, Blaise D, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 2012; 18: 289-294.
15. Gyurkocza B, Sandmaier BM,. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124: 344-353.
16. Baron F, Sandmaier BM,. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol. 2005; 12: 435-443.
17. Perez-Simon JA, Martino R, Parody R, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica. 2013; 98: 526-532.
18. Warlick ED, Paulson K, Brazauskas R, et al. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014; 20: 202-208.
19. Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007; 21: 2109-2116.
20. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18: 295-304.
21. Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014; 49: 389-396.
22. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005; 19: 2304-2312.
23. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89: 3055-3060.
24. Valcarcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2003; 31: 387-392.
25. Baron F, Sandmaier BM,. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006; 20: 1690-1700.
26. Rubio MT, Labopin M, Blaise D, et al. Impact of the intensity of the prophylactic immunosuppressive therapy in HLA-identical allogeneic stem cell transplantation for CR1 AML conditioned with a fludarabine-IV busulfan regimen: a retrospective study of the ALWP of the EBMT. Bone Marrow Transplant. 2014; 49: 2.
27. Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013; 122: 3359-3364.